JP Morgan maintains Mettler-Toledo Intl at Neutral, raises price target to $1725 from $1550

JP Morgan kept Mettler-Toledo Intl at Neutral but raised its price target to $1725 from $1550, an 11.3% increase. The new target aligns with the stock's recent close of $1722.15. Other recent analyst targets range from $1575 to $1900.

Original reporting
Published Nov 9, 2026, 8:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 8:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
JP Morgan maintains Mettler-Toledo Intl at Neutral, raises price target to $1725 from $1550 — source image
Decision brief

The 30-second read

$MTDNeutralLow
01

Why it matters

This is primarily a valuation narrative update rather than a new fundamental catalyst, so it may influence short-term sentiment more than longer-term earnings expectations.

02

Market read

For traders, the actionable element is the PT increase, which can affect near-term positioning, but the unchanged Neutral rating reduces conviction.

03

What to watch

Traders may focus more on whether other banks adjust ratings/targets after this note, since the article only summarizes JPMorgan’s stance and a recent PT range.

Relevance 4/10Novelty 4/10Timing: as of the analyst note publication date, for near-term sentiment/target-follow-through

Background

The piece summarizes JPMorgan’s latest analyst action on Mettler-Toledo Intl, including the new price target and the prior target level.

Company-level read

Ticker impact

$MTDNeutralMedium confidence
Context

JPMorgan maintained Mettler-Toledo Intl at Neutral and raised its price target to $1725 from $1550, implying a higher valuation despite no rating change.

Expected impact

Likely mild upward bias as traders price in the higher target, but follow-through may be capped given the unchanged Neutral rating.

Evidence & confidence

The article provides only an analyst price-target change and reiterates Neutral; there is no new company fundamental, guidance, or event beyond the PT update.

Market effects

Limited spillover to medical instruments/precision measurement peers because this is a single-name target change with no sector-wide catalyst.

Minimal, as the news is company-specific and not tied to a macro release.

Low, since it is not a cross-border deal, regulation, or supply-chain shock.

Counterpoint

A higher price target with a Neutral rating can be largely informational, with little incremental demand if the market already anticipates similar valuation.

Key entities

  • Mettler-Toledo International

    Subject of the analyst note summary, with JPMorgan maintaining Neutral and raising the price target to $1725.

Related articles

$MTDHighAI 8/10

Biotech funding froze. Why has this lab instrument maker climbed 25% anyway?

Mettler-Toledo's stock rose 25% despite biotech funding freeze. Management's 2026 EPS guidance of $47.70-$47.90 exceeds consensus, with 2027 guidance also above expectations. Analysts' average price target is $1,590, but some, like Jefferies, raised targets to $1,930. The company expects $900M in free cash flow, supporting an $875M share buyback. Growth drivers include pharmacopeia revisions and GLP-1 manufacturing. Investors should evaluate service revenue and hardware cycles.

$MTDMed

Biotech funding froze. Why has this lab instrument maker climbed 25% anyway? By Investing.com RSS CTA

Mettler-Toledo International (MTD) has risen 25.2% in two months, defying a biotech funding slowdown. The company, a key supplier of precision lab instruments, benefits from regulatory requirements in commercial drug production. Q3 results showed $1.09B revenue, $12.57 adjusted EPS, and strong margins. Management's 2026-2027 EPS guidance exceeds Wall Street estimates, with free cash flow supporting share buybacks.

$MTDMedAI 8/10

What Mettler-Toledo International (MTD) Said on Its Q3 Earnings Call

Mettler-Toledo (MTD) reported Q3 gross margin expansion to 59.8% and adjusted operating profit growth of 8%. The company raised its 2026 sales growth forecast to 5% and issued 2027 guidance, expecting 5% sales growth and adjusted EPS of $52.50-$53.50. Management highlighted opportunities in automation, digitalization, and U.S. onshoring, with potential upside from AI-driven instrument upgrades.

$MTDMed

Jefferies raises Mettler-Toledo stock price target on solid growth

Jefferies raised its price target for Mettler-Toledo (MTD) to $1,930, citing strong Q3 results with 6% local currency growth and improved 2026 outlook. The stock trades near its 52-week high, up 26.5% in six months. MTD reported Q3 adjusted earnings of $12.57 per share and revenue of $1.09 billion, both exceeding estimates. The company provided initial 2027 guidance with 5% growth and EPS of $52.50-$53.50, above consensus.